Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytokinetics (CYTK) Non-Current Deffered Revenue (2016 - 2022)

Historic Non-Current Deffered Revenue for Cytokinetics (CYTK) over the last 9 years, with Q1 2022 value amounting to $87.0 million.

  • Cytokinetics' Non-Current Deffered Revenue changed 0.0% to $87.0 million in Q1 2022 from the same period last year, while for Mar 2022 it was $87.0 million, marking a year-over-year change of 0.0%. This contributed to the annual value of $87.0 million for FY2021, which is 0.0% changed from last year.
  • Latest data reveals that Cytokinetics reported Non-Current Deffered Revenue of $87.0 million as of Q1 2022, which was down 0.0% from $87.0 million recorded in Q4 2021.
  • In the past 5 years, Cytokinetics' Non-Current Deffered Revenue registered a high of $87.0 million during Q4 2020, and its lowest value of $87.0 million during Q4 2020.
  • Over the past 3 years, Cytokinetics' median Non-Current Deffered Revenue value was $87.0 million (recorded in 2020), while the average stood at $87.0 million.
  • Within the past 5 years, the most significant YoY rise in Cytokinetics' Non-Current Deffered Revenue was 0.0% (2021), while the steepest drop was 0.0% (2021).
  • Over the past 3 years, Cytokinetics' Non-Current Deffered Revenue (Quarter) stood at $87.0 million in 2020, then changed by 0.0% to $87.0 million in 2021, then changed by 0.0% to $87.0 million in 2022.
  • Its last three reported values are $87.0 million in Q1 2022, $87.0 million for Q4 2021, and $87.0 million during Q3 2021.